The potential of $^1$H-MRS in CNS drug development

Alice Egerton

Received: 6 February 2019 / Accepted: 9 August 2019 / Published online: 5 September 2019
© The Author(s) 2019

Abstract
Rationale Proton magnetic resonance spectroscopy ($^1$H-MRS) is a cross-species neuroimaging technique that can measure concentrations of several brain metabolites, including glutamate and GABA. This non-invasive method has promise in developing centrally acting drugs, as it can be performed repeatedly within-subjects and be used to translate findings from the preclinical to clinical laboratory using the same imaging biomarker.

Objectives This review focuses on the utility of single-voxel $^1$H-MRS in developing novel glutamatergic or GABAergic drugs for the treatment of psychiatric disorders and includes research performed in rodent models, healthy volunteers and patient cohorts.

Results Overall, these studies indicate that $^1$H-MRS is able to detect the predicted pharmacological effects of glutamatergic or GABAergic drugs on voxel glutamate or GABA concentrations, although there is a shortage of studies examining dose-related effects. Clinical studies have applied $^1$H-MRS to better understand drug therapeutic mechanisms, including the glutamatergic effects of ketamine in depression and of acamprosate in alcohol dependence. There is an emerging interest in identifying patient subgroups with ‘high’ or ‘low’ brain regional $^1$H-MRS glutamate levels for more targeted drug development, which may require ancillary biomarkers to improve the accuracy of subgroup discrimination.

Conclusions Considerations for future research include the sensitivity of single-voxel $^1$H-MRS in detecting drug effects, inter-site measurement reliability and the interpretation of drug-induced changes in $^1$H-MRS metabolites relative to the known pharmacological molecular mechanisms. On-going technological development, in single-voxel $^1$H-MRS and in related complementary techniques, will further support applications within CNS drug discovery.

Keywords Glutamate · GABA · Magnetic resonance spectroscopy · Psychiatry · Drug development · Biomarkers

Introduction

Proton magnetic resonance spectroscopy ($^1$H-MRS) is a non-invasive in vivo technique that can be used to measure regional concentrations of brain metabolites, including glutamate and γ-amino butyric acid (GABA). A major advantage of $^1$H-MRS in central nervous system (CNS) drug discovery is that it provides a translational technique, whereby the ability of pharmacological compounds to modulate a MRS-detectable metabolite of interest in laboratory animals can then be tested in healthy humans or patient populations using the same imaging biomarker. In parallel, key findings from clinical research can be translated back to the preclinical laboratory, to develop animal disease models and test potential compounds for their ability to modulate brain metabolite abnormalities associated with CNS disorders.

This article reviews the potential of $^1$H-MRS for CNS drug development, with a focus on the development of novel glutamatergic and GABAergic compounds for the treatment of psychiatric disorders. The review describes the relevance of $^1$H-MRS-quantifiable metabolites to drug discovery, before discussing potential applications at different stages of drug development. In this emerging area, the review provides examples of applications to date and then considers the current limitations and future directions for research.

$^1$H-MRS metabolites: relevance to psychiatric drug discovery

In vivo $^1$H-MRS is an MRI-based neuroimaging approach, which is most commonly used to measure metabolites in a
predefined three-dimensional voxel, prescribed in a brain region of interest rather than across the whole brain. Depending on the magnetic field strength of the MRI scanner and acquisition sequence, it is now possible to detect over 18 metabolites in an in vivo 1H-MRS spectrum (Pfeuffer et al. 1999). Both human and rodent 1H-MRS can measure several metabolites involved in neurotransmission, oxidative stress or inflammation, which are key targets of interest for CNS drug discovery.

1H-MRS metabolites involved in excitatory and inhibitory neurotransmission

Within drug discovery for psychiatric disorders, the majority of 1H-MRS research has focussed on glutamate and GABA. At lower field strengths of around 1.5 Tesla (which corresponds to most clinical MRI scanners), glutamate and its metabolite glutamine have overlapping resonances and are usually reported in combination, termed Glx (Hancu 2009). At higher field strengths of 3 Tesla and above (corresponding to MRI scanners for clinical research), it becomes increasingly possible to resolve the glutamate and glutamine signals (Mullins et al. 2008; Snyder and Wilman 2010; Terpstra et al. 2016; Tkac et al. 2001) and their resolution may be further improved with specialised pulse sequences (Bustillo et al. 2016; Mekle et al. 2009; Wijtenburg and Knight-Scott 2011; Zhang and Shen 2016). GABA is less abundant than glutamate and has overlapping resonances with other metabolites, and detection of GABA can be facilitated through application of spectral editing, typically using Mescher-Garwood point resolved spectroscopy (MEGA-PRESS) (Puts and Edden 2012). Glutamate and glutamine may also be measurable in GABA-edited MEGA-PRESS spectra although there are challenges around their reliable quantification (Sanaei Nezhad et al. 2018).

An important consideration is that 1H-MRS quantifies the total amount of MR visible metabolite in the voxel, so glutamate levels will reflect neurotransmission but also other cellular metabolic processes. Glutamate released from synapses is rapidly converted to glutamine in astrocytes for recycling to glutamate and GABA, and this accounts for approximately 80% of glutamine synthesis (Kanamori et al. 2002; Rothman et al. 2011; Rothman et al. 1999; Sibson et al. 1997; Sibson et al. 2001). Some studies have drawn inferences about glutamate, glutamine or GABA concentrations though investigating changes in their relative ratios. Elevations in the glutamine to glutamate ratio have been interpreted as increased glutamate turnover (Brennan et al. 2010; Bustillo et al. 2010; Xu et al. 2005), and regional glutamate to GABA ratios have been discussed in the context of excitatory-inhibitory (E/I) balance (Ajram et al. 2017; Cohen Kadosh et al. 2015; Colic et al. 2018; Ferri et al. 2017; Foss-Feig et al. 2017; Gu et al. 2019). Nonetheless, the cellular mechanisms that may underpin an observed difference in the 1H-MRS glutamine/glutamate or GABA/glutamate signal ratio are complex, and when interpreting metabolite ratios it is important to consider whether the observed differences in ratios are primarily driven by the numerator or denominator.

At high field strengths, it may become possible to quantify additional glutamatergic metabolites in the 1H-MRS spectra, including glycine, serine and 3-acetylaspartylglutamate (NAAG) (discussed in Harris et al. 2017) (Fig. 1). Due to their function as N-methyl-D-aspartate (NMDA) receptor co-agonists, glycine and serine are of interest to drug discovery in psychiatric disorders associated with NMDA receptor dysfunction, most prominently schizophrenia (Goff 2015; Stern et al. 2007).
Moghaddam and Javitt 2012). Glycine and serine also act as inhibitory neurotransmitters through activating glycine receptors-chloride channels (Legendre 2001). In man, glycine has been measured at field strengths of 3 T or more using specialised sequences (Kaufman et al. 2009; Kim et al. 2017; Prescott et al. 2006; Tiwari et al. 2017), while the detection of serine remains more challenging (Harris et al. 2017).

NAAG, present in neurons and glia, is a neuromodulatory peptide that acts as an agonist at mGluR3 receptors to decrease neurotransmitter release (see Neale et al. 2011). NAAG can also act as a NMDA receptor antagonist (Bergeron et al. 2007) or agonist (Westbrook et al. 1986) depending on the cellular environment and subunit composition of the NMDA receptors, among other factors (Khacho et al. 2015). Compounds that increase NAAG, such as NAAG peptidase inhibitors, may have therapeutic effects that may be associated with mGluR2/3 agonism, including antipsychotic effects (Olszewski et al. 2004) or decreasing additive behaviours (Xi et al. 2010a, b). While it may be possible to isolate NAAG from the larger N-acetylaspartate (NAA) signal using spectral editing at human field strengths (Edden et al. 2007; Harris et al. 2017), few studies have used these techniques (Jessen et al. 2011; Landim et al. 2016; Rowland et al. 2013).

1H-MRS metabolites as markers of brain inflammation or oxidative stress

Also relevant to drug discovery in psychiatric disorders are 1H-MRS metabolites that act as antioxidants and markers of brain inflammation. Myo-inositol (mIns), a precursor of the phosphatidylinositol membrane lipids (Berridge and Irvine 1989) and choline-containing compounds (phosphocholine and glycerophosphocholine) are predominantly expressed in glial cells (Brand et al. 1993; Urenjak et al. 1993). Both mIns and choline have been interpreted as markers of glial activation, which may provide a proxy measure of inflammation (Edden et al. 2005; Venkatraman et al. 2009) and schizophrenia (Bojesen et al. 2018; Javitt et al. 2018; Kraguljac et al. 2017; Rowland et al. 2005; Stone et al. 2012).

Potential applications of 1H-MRS in drug development

1H-MRS could potentially be applied to accelerate CNS drug discovery at various stages of the drug development pipeline, either alone or in combination with other imaging modalities (Wong et al. 2009). This is an emerging application of 1H-MRS within psychiatry. As such, the following section discusses the potential of this approach using examples where they are already available and considers the future developments that are required to support wider implementation. Box 1 provides selected examples of current 1H-MRS applications, and Box 2 summarises key considerations for future research.

Box 1: Selected examples of current applications of 1H-MRS in psychiatric research and CNS drug development

Translation of rodent models to man
Example: Increases in frontal or hippocampal glutamatergic metabolites occurring on ketamine administration, as a cross-species model of NMDA hypofunction in schizophrenia (Bojesen et al. 2018; Javitt et al. 2018; Kraguljac et al. 2017; Rowland et al. 2005; Stone et al. 2012).

Understanding drug therapeutic mechanisms
Example: Ketamine-induced changes in frontal or occipital glutamate in relation to antidepressant efficacy (Evans et al. 2018; Milak et al. 2016; Valentine et al. 2011).

Target engagement
Example: Increases in prefrontal glutamate metabolites and GABA on d-cycloserine administration (Kantrowitz et al. 2016).

Preclinical model development
Example: Effects of maternal immune activation, a risk factor for psychiatric disorders in offspring, on brain metabolites during rat developmental maturation (Vernon et al. 2015).

Refining the therapeutic rationale
Example: Linking pre-treatment glutamate levels to the degree of subsequent clinical response in first episode psychosis (Egerton et al. 2018; Szule et al. 2013) or in bipolar disorder (Strawn et al. 2012).
Box 2: Key considerations for $^1$H-MRS in psychiatric research and CNS drug development.

The extent to which $^1$H-MRS can detect dose-dependent drug effects at clinically relevant doses in man. Whether the signal change in pharmacomRS studies is of sufficient magnitude and reliability to investigate the ability of second compound to attenuate the drug effect. Unclear relationships between pharmacological molecular mechanisms and $^1$H-MRS metabolite signal change. Issues around standardisation of data acquisition, read-out, intra and inter-site reliability, particularly for multicentre studies.

Biomarkers for target engagement

A first potential application of $^1$H-MRS is to employ pharmacologically induced changes in the $^1$H-MRS metabolite of interest (pharmacological MRS ‘pharmacomRS’) as a biomarker of target engagement (TE). In preclinical studies, the most promising drug candidates could be selected from a series of compounds by examining their ability to modulate the target metabolite. A similar approach could assist dose selection of the candidate compound. Lead compounds could then be translated to human $^1$H-MRS studies using the same $^1$H-MRS TE biomarker for confirmation, before proceeding to clinical trials.

Application of $^1$H-MRS for TE requires prior confirmation that $^1$H-MRS has sensitivity to detect pharmacologically evoked changes in brain metabolites at relevant doses, and that these changes are consistent with established pharmacological drug effects (see Waschkies et al. 2014). Within psychiatric drug development, preclinical and clinical $^1$H-MRS studies have mainly investigated the effects of glutamatergic and GABAergic compounds (Table 1). Studies examining glutamatergic metabolites have variously reported changes in Glx, glutamate or glutamine. As discussed above, the reported glutamatergic metabolites will reflect the methodological features of the study that determine the ability to resolve signals from glutamine from glutamate, as well as potentially differential biological effects of the pharmacological challenge on glutamate versus glutamine concentrations. While there are some negative findings, overall, these studies indicate that $^1$H-MRS has sensitivity to detect the hypothesised drug effects, and that comparable effects can be observed in rodent and human pharmacomRS.

A number of $^1$H-MRS studies have now examined the effects of administration of NMDA antagonists such as ketamine (Table 1), which are expected to increase extracellular glutamate (Moghaddam et al. 1997). Ketamine has mainly been investigated as an experimental model of NMDA hypofunction in schizophrenia (Bojesen et al. 2018; Javitt et al. 2018; Kraguljac et al. 2017; Rowland et al. 2005; Stone et al. 2012), or in relation to its antidepressant effects (Evans et al. 2018; Li et al. 2017; Milak et al. 2016; Taylor et al. 2012; Valentine et al. 2011). As hypothesised, several studies have observed increases in the glutamate, glutamine or Glx signal following NMDA antagonist administration, both in experimental animals (Ilitis et al. 2009; Kim et al. 2011; Lee et al. 2010; Napolitano et al. 2014) and in man (Javitt et al. 2018; Kraguljac et al. 2017; Li et al. 2017; Milak et al. 2016; Rowland et al. 2005; Stone et al. 2012). However, some studies have not observed any changes in glutamatergic metabolites (Bojesen et al. 2018; Evans et al. 2018; Rodriguez et al. 2015; Sekar et al. 2018; Servaes et al. 2019; Taylor et al. 2012; Valentine et al. 2011; Yoo et al. 2017). Increases in Glx in the human medial prefrontal cortex were also observed after a single administration of NMDA receptor glycine site partial agonist D-cycloserine, which like ketamine is of interest as an antidepressant (Kantrowitz et al. 2016). Conversely, the few studies examining administration of glycine site agonists, which may be predicted to reduce glutamate levels via increased NMDA receptor activation, have produced mixed results; no difference in glutamate was apparent after 2 weeks of glycine administration (Kaufman et al. 2009), and in patients with schizophrenia, 6 months of sarcosine produced regional dependence in Glx (Strzelecki et al. 2015a, b). Decreases in glutamatergic metabolites (glutamate, glutamine or Glx) have been observed across species following administration of several other compounds, including n-acetylcysteine (das Neves Duarte et al. 2012; Durieux et al. 2015; McQueen et al. 2018; O’Gorman Tuura et al. 2019; Schmaal et al. 2012), riluzole (Rizzo et al. 2017; Waschkies et al. 2014) and acamprosate (Frye et al. 2016; Umhau et al. 2010), although again not without some negative or discrepant findings (Table 1) (Brennan et al. 2010; Das et al. 2013; Girgis et al. 2019; Pillinger et al. 2019; Schulte et al. 2017).

There are fewer studies examining GABAergic compounds. In rats, $^1$H-MRS GABA levels show the predicted increases on administration of the GABA-transaminase inhibitor vigabatrin (de Graaf et al. 2006; Patel et al. 2006; Waschkies et al. 2014), or GABA transporter inhibitor tiagabine (Waschkies et al. 2014), and decreases on administration of 3-mercaptopropionate (3-MP), a glutamic acid decarboxylase inhibitor (Waschkies et al. 2014). The only human $^1$H-MRS study investigating administration of a GABAergic compound, tiagabine, did not observe significant change in GABA (Myers et al. 2014).

To investigate whether $^1$H-MRS glutamate and GABA are sensitive to dose-dependent effects, Waschkies et al. (2014) examined a range of doses of five glutamatergic or GABAergic compounds (vigabatrin, 3-mercaptopropionate, tiagabine, methionine sulfoximine and riluzole) in rats. Dose-related effects were detected in the frontal cortex and striatum, which should be confirmed in further rodent studies.
| Author                  | Subject         | Compound, design                      | Dosing                        | Voxel location | Results                                                                 |
|------------------------|-----------------|---------------------------------------|-------------------------------|----------------|-------------------------------------------------------------------------|
| **NMDA receptor antagonists** |                 |                                       |                               |                |                                                                         |
| Iltis et al. (2009)    | Rat             | Phencyclidine vs. saline              | 10 mg/kg i.p.                 | PFC            | Increase in Glu/Glu; NS for Glu, Gln                                    |
| Lee et al. (2010)      | Dog             | Ketamine vs. pentobarbital anaesthesia| 15 mg/kg i.v.                 | Striatum       | Increase in Glu                                                          |
| Kim et al. (2011)      | Rat             | Ketamine vs. saline                   | 30 mg/kg for 6 days           | PFC            | Increase in Glu in group-housed, decrease in GABA in isolated group      |
| Napolitano et al. (2014) | Rat           | Ketamine vs. saline                   | 25 mg/kg i.p.                 | ACC/mFC        | NS for Glu, Gln                                                         |
| Yoo et al. (2017)      | Rat             | MK-801 vs. saline                     | 0.5 mg/kg for 6 days          | PFC            | NS for Glu, GABA                                                        |
| Sekar et al. (2018)    | Rat             | Memantine vs. vehicle                 | 20 mg/kg/day i.p. for 5 days  | Hippocampus    | NS for Glu, decreases in GABA in isolated group.                        |
| Servaes et al. (2019)  | Rat             | MK-801 or ebselen vs. saline          | 0.3 mg/kg i.p., ebselen       | Striatum       | NS for Glu, decrease in GABA in ebselen group.                         |
| Rowland et al. (2005)  | Human (HV)      | Ketamine vs. placebo, crossover       | Loading 0.27 mg/kg over 10 min; maintenance 0.00225 mg/kg/min for up to 2 h | ACC            | Increase in Gln during loading dose, NS for Glu                          |
| Valentine et al. (2011)| Human (MDD)     | Ketamine vs. saline pre-post          | 0.5 mg/kg over 40 min         | OCC            | NS for Glu, Gln, GABA                                                  |
| Taylor et al. (2012)   | Human (HV)      | Ketamine vs. placebo, parallel group  | 0.5 mg/kg over 40 min         | ACC            | NS for Glu or Glx                                                       |
| Stone et al. (2012)    | Human (HV)      | Ketamine, pre-post                    | 0.26 mg/kg bolus then 0.42 mg/kg/h | ACC (Glu) and thalamus (GABA) | Increase in ACC Glu, NS for Glu or GABA, 25–35 min after bolus          |
| Milak et al. (2016)    | Human (MDD)     | Ketamine pre-post                     | 0.5 mg/kg over 40 min         | mPFC           | Increase in Glu and GABA over 40 min                                   |
| Rodriguez et al. (2015)| Human (OCD)    | Ketamine vs. placebo, crossover       | 0.5 mg/kg over 40 min         | mPFC           | Increase in GABA; NS for Glx over 60 min                               |
| Li et al. (2017)       | Human (HV)      | Ketamine vs. placebo, parallel group  | 0.5 mg/kg over 40 min         | pgACC and aMCC | Increase in Gln/Glu in pgACC at 24 h but not 1 h post-ketamine          |
| Kraguljac et al. (2017)| Human (HV)     | Ketamine pre-post                     | 0.27 mg/kg over 10 min, then 0.25 mg/kg/h for 50 min | Left hippocampus | Increase in Glx                                                        |
| Bojesen et al. (2018)  | Human (HV)      | S-Ketamine, pre-post                  | Loading 0.25 mg/kg for 20 min, maintenance 0.125 mg/kg for 20 min | ACC, thalamus | NS for Glu, Glx or Gln                                                 |
| Javitt et al. (2018)   | Human (HV)      | Ketamine vs. placebo, parallel group. | 0.23 mg/kg for 1 min, then 0.58 mg/kg/h over 30 min, then 0.29 mg/kg/h over 29 min | ACC (mPFC)     | Increase Gls over first 15 min, NS between 15 and 60 min               |
| Evans et al. (2018)    | Human (HV and MDD) | Ketamine vs placebo, crossover       | 0.5 mg/kg over 40 min         | pgACC          | Glu NS in both HV and MDD at 24 h post-ketamine                         |
| **NMDA glycine site agonists (direct or indirect)** |                 |                                       |                               |                |                                                                         |
| Kaufman et al. (2009)  | Human (HV)      | Glycine                               | 0.2 to 0.8 g/day for 2 weeks  | OCC            | Increase in Gly; NS for Glu                                            |
| Strzelecki et al. (2015b)| Human (SCZ)   | Sarcoseine vs. placebo parallel group | 2 g/day for 6 months          | Left frontal white matter | Increase in Glx                                                        |
| Strzelecki et al. (2015c)| Human (SCZ)   | Sarcoseine vs. placebo parallel group | 2 g/day for 6 months          | Left dIPFC     | Glx NS                                                                 |
| Strzelecki et al. (2015a)| Human (SCZ)   | Sarcoseine vs. placebo parallel group | 2 g/day for 6 months          | Left Hippocampus | Decrease in Glx                                                        |
| Kantrowitz et al. (2016)| Human         | d-Cycloserine, pre-post               | 1000 mg                       | mPFC           | Increase in Glx                                                        |
| Author | Subject | Compound, design | Dosing | Voxel location | Results |
|--------|---------|------------------|--------|----------------|---------|
| Durieux et al. (2015) | Mouse | N-acetylcysteine vs. vehicle | 150 mg/kg i.p. | Left striatum | Decrease Glu |
| das Neves Duarte et al. (2012) | Mouse | N-acetylcysteine | 2.4 g/L in drinking water during development | Anterior cortex | Decrease Gln and Gln:Glu; Glu NS |
| Schmaal et al. (2012) | Human (cocaine-dependent) | N-acetylcysteine vs. placebo crossover | 2.4 g single oral dose | ACC | Decrease Glu |
| Das et al. (2013) | Human (MDD) | N-acetylcysteine vs. placebo, parallel group | 2 g/day for 12 weeks | mPFC | Increase Glx |
| Comus et al. (2018) | Human (EP) | N-acetylcysteine vs. placebo, parallel group | 2.7 g/day for 6 months | mPFC | Glu, Gln, Gln:Glu NS |
| Schulte et al. (2017) | Human (smokers) | N-acetylcysteine vs. placebo, parallel group | 2.4 g/day for 14 days | ACC | Glx, GABA NS |
| McQueen et al. (2018) | Human (SCZ) | N-acetylcysteine vs. placebo crossover | 2.4 g single oral dose | ACC, right caudate | Decrease Glx in ACC, Glu NS. |
| Girgis et al. (2019) | Human (HV and SCZ) | N-acetylcysteine, pre-post | 2.4 g single oral dose | dACC, mPFC | Glu, Gln, NS |
| O’Gorman Tuura et al. (2019) | Human (HV) | N-acetylcysteine vs. no intervention, crossover | 5 g i.v. over 1 h | PFC, striatum | Striatum: decrease Glx, Gln; PFC decrease Glx; Glu NS. |
| Riluzole | Waschkies et al. (2014) | Rat | Riluzole vs. vehicle | 3, 6, and 12 mg/kg i.p | PFC, striatum | PFC and striatum decrease Glu |
| Rizzo et al. (2017) | Rat | Riluzole vs. vehicle | 6 mg/kg/day i.p, 15 days | Left mPFC, left striatum | In hypertensive but not control rats, decrease PFC Glu and Gln; GABA NS |
| Brennan et al. (2010) | Human (BPD) | Riluzole, pre-post | 100-200 mg/day for 6 weeks | ACC, POC | Increase in Gln/Glu between days 0–2 |
| Ajram et al. (2017) | Human (HV and ASD) | Riluzole vs placebo, crossover | 50 mg oral single dose | dIPFC | Increased GABA/GABA + Glx in HV; Decreased GABA/GABA + Glx in ASD |
| Pillinger et al. (2019) | Human (HV and SCZ) | Riluzole, pre-post | 50 mg twice daily for 2 days | ACC | Group by condition interaction related to Glx decrease in SCZ and increase in HV |
| Other glutamatergic drugs | Waschkies et al. (2014) | Rat | MSO vs. vehicle | 50, 100, and 200 mg/kg i.p | PFC, striatum | PFC; dose-dependent decrease Glu increase Gln; striatum: decrease GABA increase Glu |
| Godlewksa et al. (2018) | Human (BPD) | Lamotrigine, pre-post | TAU, 10–12 weeks | ACC | Glx NS |
| Umhau et al. (2010) | Human (alcohol dependence) | Acamprosate, pre-post | oral loading followed by 1998 mg daily for 4 weeks | ACC | Decrease Glu |
| Frye et al. (2016) | Human (alcohol dependence) | Acamprosate, pre-post | 4 weeks | ACC | Decrease Glu |
| GABAergic drugs | Waschkies et al. (2014) | Rat | Vigabatrin vs. vehicle | 30, 100, and 300 mg/kg i.p | PFC, striatum | Dose-dependent increase in GABA in PFC and striatum, decrease in |

---

Note: MSO refers to monosodium glutamate.
To date, human $^1$H-MRS studies of acute glutamatergic or GABAergic drug effects have only investigated single doses (Table 1). Whether $^1$H-MRS has sensitivity to detect dose-related changes in glutamate and GABA metabolites in man within acceptable human dose ranges therefore remains to be established.

Research into the development of glutamate-targeting drugs for schizophrenia has provided some examples of how $^1$H-MRS TE biomarkers might be applied in early phase clinical trials. The variability with which symptoms of schizophrenia improve during adjunctive glycine treatment may partially depend on individual differences in glycine CNS penetration (Kaufman et al. 2009). In healthy volunteers, Kaufman et al. (2009) showed that $^1$H-MRS was able to detect increases in brain glycine levels over 2 weeks of glycine administration. In further clinical trials of compounds designed to increase glycine concentrations in patients, $^1$H-MRS could be used to measure the extent of TE and relationship with efficacy. As a similar example, $^1$H-MRS has been applied as a marker of TE in a clinical trial of the antioxidant and glutathione (GSH) precursor $n$-acetylcysteine (Conus et al. 2018). In patients with early psychosis, significant increases (22.6%) in medial prefrontal cortex GSH levels were observed after 6 months of administration of $N$-acetylcysteine but not placebo, indicating $N$-acetylcysteine TE (Conus et al. 2018). A final example concerns the attenuation of ketamine-induced increases in $^1$H-MRS Glx as a biomarker for TE in early stage clinical trials of novel glutamatergic compounds (Javitt et al. 2018). This multicentre study detected ketamine-induced increases in Glx in the medial frontal cortex with a moderate effect size of $d = 0.6$, although this may not provide sufficient power for reliably detecting subsequent reversal by glutamatergic compounds (Javitt et al. 2018). Similar applications of $^1$H-MRS may be strengthened by the combination of $^1$H-MRS with other biomarkers of TE in a multimodal approach as well as technical refinements to increase sensitivity.

**Preclinical model development**

A second application of $^1$H-MRS within drug development is to translate findings in clinical populations back to animal models, to determine the validity of the model in recapitulating the neurochemical abnormality seen in the patient population using the same imaging technique. As a next step, the ability of pharmacological compounds to restore levels of $^1$H-MRS metabolites to control levels may then be used as a translational predictive biomarker for efficacy.

A key advantage of $^1$H-MRS in animal models is that data can be acquired repeatedly in the same animal, to provide longitudinal studies of drug effects. For example, this has allowed investigation of the effects of psychoactive bacteria on brain neurometabolites and how these respond after cessation of treatment (Janik et al. 2016), the changes in brain
metabolites in rats exposed to maternal immune activation as they develop through adolescence into adulthood (Vernon et al. 2015) and the effects of pharmacological interventions on the emerging developmental abnormalities in genetically modified compared to wild-type mice (das Neves Duarte et al. 2012). These types of within-subject studies may also bring statistical advantages and reduce the numbers of experimental animals required.

**Refining the therapeutic rationale and patient stratification**

Within psychiatric disorders, $^1$H-MRS research has not revealed a clear abnormality in brain metabolites that could be used diagnostically (as is the case for other biological measures). $^1$H-MRS glutamate studies comparing patients with schizophrenia to healthy volunteers have produced mixed findings, which may be related to illness stage, antipsychotic effects or other factors (Marsman et al. 2011; Merritt et al. 2016). In major depressive disorder (Moriguchi et al. 2018) and bipolar disorder (Taylor 2014), $^1$H-MRS studies may also indicate subgroups of patients within the diagnosis. Understanding this biological heterogeneity within a given diagnostic category may be a crucial factor in successful drug development. This raises the possibility that $^1$H-MRS measures could be used as a biomarker for intermediate phenotypes, to identify the subgroup of patients who are more likely to respond to a particular pharmacological intervention, and to stratify patients for clinical trials of this intervention.

While this is an emerging area of research, there is some early evidence to support the use of $^1$H-MRS in refining the therapeutic rationale and clinical trial stratification. Measures of glutamatergic $^1$H-MRS metabolites prior to starting a pharmacological treatment have been associated with the subsequent degree of response to a number of compounds, including antipsychotics in patients with first episode psychosis or established schizophrenia (Egerton et al. 2018; Szule et al. 2013), ketamine in major depressive disorder (Salvadore et al. 2012) or valproate in bipolar disorder (Strawn et al. 2012). However, although these studies provide information on biological factors that may influence the degree of response to glutamatergic drugs, significant further work is needed before $^1$H-MRS can be used to pre-select patient subgroups for stratified clinical trials. This would require reproducible data to define cut-off values for the level of the metabolite of interest that can most accurately predict the subgroup likely to respond to the intervention and knowledge of the accuracy of the prediction. While $^1$H-MRS metabolite levels alone may not provide sufficient predictive accuracy for stratification, potentially the degree of accuracy could be improved through combination with other predictive variables (Egerton et al. 2018). Moreover, in the context of large clinical trials involving multiple recruitment sites, the non-trivial issues of standardisation of $^1$H-MRS acquisition and data values for patient selection across sites would be necessary. Research into the development of glutamatergic drugs for depression, schizophrenia or other disorders has revealed inverted U or non-linear dose-response relationships (Abdallah et al. 2018b; Foss-Feig et al. 2017). This suggests that measurement of pre-treatment levels of glutamatergic function may be important in identifying patient subgroups more likely to respond to novel glutamate-acting drugs, but may also complicate the use of $^1$H-MRS glutamate measures for patient stratification or dose selection.

Other studies have found no relationship between pre-treatment metabolite levels and response, but instead indicate that the degree of change in metabolite levels during treatment may mediate the extent of symptomatic improvement (Brennan et al. 2017; de la Fuente-Sandoval et al. 2013; Godlewksa et al. 2018; Goff et al. 2002). In addition to providing mechanistic information, these studies are interesting in that they may suggest that early changes in glutamate metabolites occurring within the first 1–2 weeks of treatment may predict longer-term clinical outcomes. Such treatment-emergent biomarkers could be used in adaptive clinical trial design, where early ‘brain-level’ indicators of response could inform the treatment paradigm. As this approach would centre on the within-subjects change in $^1$H-MRS metabolite level rather than an individual value at a single time-point, some issues relating to standardisation of $^1$H-MRS data across multiple sites may be reduced.

**General limitations and future directions**

A main limitation of $^1$H-MRS is that it measures the total voxel concentration of the MR-visible metabolite, across all cellular compartments. In glutamatergic or GABAergic drug development studies, this indirect measure of TE may limit the sensitivity and interpretation, as the relationship between interaction at the molecular drug target and the change in the total MR-visible glutamate or GABA signal may be non-linear or uncertain. As $^1$H-MRS is a technique that is translatable across species, combination with invasive methodologies in rodents such as microdialysis or fast-scan cyclic voltammetry could aid interpretation of the $^1$H-MRS signal. Where feasible, $^1$H-MRS could also be combined with more direct measures of target engagement in both humans and other animals, such as glutamate receptor occupancy as measured using positron emission tomography (PET) (Gruber and Amentamey 2017).

There is also on-going development of complementary MRS approaches that may provide deeper information on glutamatergic signalling. The far more technically challenging technique of carbon-13 magnetic resonance spectroscopy ($^{13}$C-MRS) can measure glutamate-glutamine cycling by
following the flow of a $^{13}$C isotope through the tricarboxylic acid cycle (see Rothman et al. 2011). To date, the application of $^{13}$C-MRS has been limited by technical complexity, sensitivity, spatial resolution and other factors, but with future technological advances, this technique may be of significant application to glutamatergic drug development. Indeed, a recent human study of ketamine using $^{13}$C-MRS found increases in prefrontal $^{13}$C glutamine enrichment, indicating increased glutamate-glutamine cycling (Abdallah et al. 2018a).

Also of interest is functional $^1$H-magnetic resonance spectroscopy (fMRS), which measures the dynamic change in the $^1$H-MRS metabolite signal occurring in response to a stimulus. Glutamate fMRS studies have detected stimulus-induced increases averaging 7% across experimental designs, and to the order of 13% in event-related studies (Mullins 2018). The greater magnitude of change detected in event-related compared to stimulus-block designs may relate to the relative rapidity of glutamate dynamics within the timeframe of the stimulation block, during which habituation, adaptation or homeostatic processes may occur (Apsvalka et al. 2015; Jelen et al. 2018). There are several potential explanations for magnitude of change in the fMRS signal, including increases in glutamate production from glucose oxidative metabolism (Mangia et al. 2007), compartmental shifts in glutamate from less (presynaptic vesicles) to more (extracellular) MRS-visible pools (Jelen et al. 2018; Kauppinen et al. 1994; Mullins 2018) and influences of blood oxygen level dependent (BOLD)-like effects on the signal amplitude (Apsvalka et al. 2015; Jelen et al. 2018). Pharmacological modulation of glutamate dynamics using fMRS is yet to be investigated and will be an interesting area for future research.

While the studies included in this review have investigated $^1$H-MRS metabolites serially in single voxels, it is also possible to measure multiple voxels simultaneously using MR spectroscopic imaging (MRSI). While initially limited to the more easily detectable metabolites such as NAA, $^1$H-MRSI sequences are now available to measure Glx (Ding et al. 2015; Gasparovic et al. 2011; Steel et al. 2018), glutamate and glutamine (Goryawala et al. 2016; Henning et al. 2009) and GABA (Moser et al. 2019) across large volumes of interest or the whole brain with a feasible short acquisition time. Within psychiatric disorders, $^1$H-MRSI is therefore able to map the spatial distribution of metabolite abnormalities, which could provide richer regional information for future drug development. Finally, glutamate drug development could exploit the recent MRI technique of glutamate chemical exchange saturation transfer (GluCEST) (Cai et al. 2012), which has greater sensitivity, spatial and temporal for glutamate measurement than $^1$H-MRS.

$^1$H-MRS studies in rodents are usually limited by the necessary use of anaesthesia to reduce stress to the animal and movement in the scanner, which will affect several aspects of brain physiology including metabolite concentrations (Makaryus et al. 2011) and could lead to divergence between results of preclinical and clinical studies. Under a typical protocol, in vivo $^1$H-MRS scanning takes approximately 1 hour per rat and can be associated with high costs of preclinical MRI equipment access or purchase, meaning it is probably impractical for initial drug screening. For a simple between-subjects group comparison, Waschkies et al. (2014) estimate that eight animals per group are required to detect a 6% change in glutamate, 12% change in GABA or 16% in glutamine (power = 80%; $\alpha$ = 5%), which is comparable to group sizes commonly required for invasive metabolite measurement. The authors also report good consistency of $^1$H-MRS measurement over time and across different batches of animals (Waschkies et al. 2014), which should be also established in other laboratories employing preclinical $^1$H-MRS. Despite the higher MR field strengths available for preclinical studies, the small voxel sizes required in relation to the rodent brain can limit detection of less abundant metabolites.

For human studies, participation in $^1$H-MRS requires that volunteers meet standard MRI inclusion criteria, such as an absence of implanted metallic objects. Typically, a $^1$H-MRS data acquisition to measure glutamate in a single voxel of ~8 ml would take about 10 minutes, with smaller voxels requiring longer acquisition times to obtain an equivalent signal to noise ratio. The short length of scan can generally be well tolerated by most individuals and patient groups. $^1$H-MRS data can be acquired as part of a set of MRI acquisition sequences, for example permitting MRS metabolite data to be investigated in relation to brain resting or functional activity during the same session. As mentioned above, it may be that multimodal imaging data could provide more reliable or accurate estimates for target engagement or patient stratification, as well as providing more comprehensive information on drug mechanism, and application of $^1$H-MRS to larger clinical studies across several study sites will benefit from protocol standardisation and evaluation of both inter- and intra-site reliability. Finally, with the availability of higher field strength MRI scanners for human research studies, it becomes increasingly possible to resolve lower concentration metabolites such as GABA or glutathione and separate glutamate and glutamine resonances under optimal acquisition sequences.

**Conclusion**

There has been a growing interest in applying $^1$H-MRS to CNS drug discovery, including in the development of glutamate-acting compounds for psychiatric disorders. A key advantage of $^1$H-MRS is that it is a non-invasive technique that can directly translate findings from rodents to man using the same imaging biomarker which can be acquired repeatedly within subjects. An increasing number of experiments across species indicate that $^1$H-MRS has sensitivity to measure the predicted pharmacological effects of glutamatergic and
GABAergic compounds at clinically relevant doses, and there are early indications that some 1H-MRS metabolite measures may contribute to identifying patient subgroups for stratified approaches to clinical trials. This research would be assisted through further methodological studies to measure and improve the reliability and sensitivity of 1H-MRS metabolite measurements, especially for multicentre application. Ongoing technological and methodological development, including high field strength MRI, optimised acquisition sequences, 13C-MRS and fMRS, may further support applications of MRS in CNS drug discovery.

Acknowledgements Dr. Anthony Vernon at King’s College London kindly provided the representative 1H-MRS spectra in the rat brain shown in Fig. 1.

Funding information This review relates to work performed under UK Medical Research Council (MRC) grant MR/L003988/1 and is also supported in part by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley National Health Service (NHS) Foundation Trust and King’s College London. The views expressed are those of the author and do not necessarily represent those of the NHS, NIHR or Department of Health.

Compliance with ethical standards

Conflict of interest The author declares that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GML, Purohit P, de Graaf RA, Esterlis I, Juchem C, Pittman BP, Krystal JH, Rothman DL, Sanacora G, Mason GF (2018a) The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology 43:2154–2160

Abdallah CG, Sanacora G, Duman RS, Krystal JH (2018b) The neurobiology of depression, ketamine and rapid-acting antidepressants: is it glutamate inhibition or activation? Pharmacol Ther 190:148–158

Ajram LA, Horder J, Mendez MA, Galanopoulos A, Brennan LP, Wikchers RH, Robertson DM, Murphy CM, Zinkstok J, Ivin G, Heasman M, Meek D, Tricklebank MD, Barker GF, Lythgoe DJ, Edden RAE, Williams SC, Murphy DGM, McAlonan GM (2017) Shifting brain inhibitory balance and connectivity of the prefrontal cortex of adults with autism spectrum disorder. Transl Psychiatry 7: e1137

Apsvalka D, Gadie A, Clemence M, Mullins PG (2015) Event-related dynamics of glutamate and BOLD effects measured using functional magnetic resonance spectroscopy (fMRS) at 3T in a repetition suppression paradigm. Neuroimage 118:292–300

Ariyannur PS, Arun P, Barry ES, Andrews-Shigaki B, Bosomtwi A, Tang H, Selwyn R, Grunberg NE, Moffett JR, Namboodiri AM (2013) Do reductions in brain N-acetylaspartate levels contribute to the etiology of some neuropsychiatric disorders? J Neurosci Res 91:934–942

Bagory M, Durand-Dubief F, Ibarrola D, Comte JC, Cotton F, Confavreux C, Sappey-Marinier D (2012) Implementation of an absolute brain 1H-MRS quantification method to assess different tissue alterations in multiple sclerosis. IEEE Trans Biomed Eng 59:2687–2694

Bergeron R, Imamura Y, Frangioni JV, Greene RW, Coyle JT (2007) Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. J Neurochem 100:346–357

Berridge MJ, Irvine RF (1989) Inositol phosphates and cell signalling. Nature 341:197–205

Bojesen KB, Andersen KA, Rasmussen SN, Baandrup L, Madsen LM, Glenthoj BY, Rostrup E, Broberg BV (2015) Glutamate levels and resting cerebral blood flow in anterior cingulate cortex are associated at rest and immediately following infusion of S-ketamine in healthy volunteers. Front Psychiatry 9:22

Brand A, Richter-Landsberg C, Leibfritz D (1993) Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 15:289–298

Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescot AP, Cohen BM, Pope HG Jr, Renshaw PF, Ongur D (2010) Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with rituxime. Neuropsychopharmacology 35:834–846

Brennan BP, Admon R, Perriello C, LaFlamme EM, Athey AJ, Pizzagalli DA, Hudson JI, Pope HG Jr, Jensen JE (2017) Acute change in anterior cingulate cortex GABA, but not glutamine/glutamate, mediates antidepressant response to citalopram. Psychiatry Res Neuroimaging 269:9–16

Brugger S, Davis JM, Leucht S, Stone JM (2011) Proton magnetic resonance spectroscopy and illness stage in schizophrenia–a systematic review and meta-analysis. Biol Psychiatry 69:495–503

Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C, Hammond R, Brooks WM, Lauriejo J (2010) (1)H-MRS at 4 Tesla in minimally treated early schizophrenia. Mol Psychiatry 629–636

Bustillo JR, Rediske N, Jones T, Rowland LM, Abbott C, Wijtenburg SA (2016) Reproducibility of phase rotation stimulated echo acquisition mode at 3T in schizophrenia: emphasis on glutamine. Magn Reson Med 75:498–502

Caetano SC, Fonseca M, Verola RL, Nicolleti M, Hatch JP, Stanley JA, Hunter K, Lafer B, Pliszka SR, Soares JC (2005) Proton spectroscopy study of the left dorsolateral prefrontal cortex in pediatric depressed patients. Neurosci Lett 384:321–326

Cai K, Haris M, Singh A, Kogan F, Greenberg JH, Hariharan H, Detre JA, Reddy R (2012) Magnetic resonance imaging of glutamate. Nat Med 18:302–306

Chang L, Lee PL, Yiannoutsos CT, Ernst T, Marra CM, Richards T, Kolson D, Schifitto G, Jarvik JG, Miller EN, Lenkinski R, Gonzalez G, Nava BA, Consortium HM (2004) A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage 23:1336–1347

Chang L, Munsaka SM, Kraft-Terry S, Ernst T (2013) Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain. J Neuroimmune Pharmacol 8:576–593

Cohen Kadosh K, Krause B, King AJ, Near J, Cohen Kadosh R (2015) Linking GABA and glutamate levels to cognitive skill acquisition during development. Hum Brain Mapp 36:4334–4345

Colic L, Li M, Demenscuc LR, Li S, Muller I, Richter A, Behnisch G, Seidenbecher CI, Speck O, Schott BH, Stork O, Walter M (2018) GAD65 promoter polymorphism rs2236418 modulates harm
Kantrowitz JT, Milak MS, Mao X, Shungu DC, Mann JJ (2016) D-Cycloserine, an NMDA glutamate glycine site partial agonist, induces acute increases in brain glutamate plus glutamine and GABA comparable to ketamine. Am J Psychiatry 173:1241–1242
Kaufman MJ, Prescott AP, Ongur D, Ewins AE, Barros TL, Medeiros CL, Covell J, Wang L, Fava M, Renshaw PF (2009) Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. Psychiatry Res 173
Kaurpinen RA, Pirttila TR, Auriola SO, Williams SR (1994) Kirov II, Patil V, Babb JS, Rusinek H, Herbert J, Gonen O (2009) MR
Kim SY, Lee H, Kim BJ, Eun H, Lee SH, Lee DW, Woo DC, Choi CB, Hong KS, Lee C, Choe BY (2011) In vivo and ex vivo evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: potential relevance to schizophrenia. NMR Biomed 24:1235–1242
Kim SY, Kaufman MJ, Cohen BM, Jensen JE, Coyle JT, Du F, Ongur D (2017) In vivo brain glycine and glutamate concentrations in patients with first-episode psychosis measured by echo time-averaged proton magnetic resonance spectroscopy at 4T. Biol Psychiatry
Kirov II, Patil V, Babb JS, Rasinek H, Herbert J, Gonen O (2009) MR spectroscopy indicates diffuse multiple sclerosis activity during remission. J Neurol Neurosurg Psychiatry 80:1330–1336
Kraguljac NV, Reid M, White D, Jones R, de Hollander J, Lowman D, Lahti AC (2012) Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis. Psychiatry Res 203:111–125
Kraguljac NV, Frolich MA, Tran S, White DM, Nichols N, Barton-McArdule A, Reid MA, Bolding MS, Lahti AC (2017) Ketamine modulates hippocampal neurochemistry and functional connectivity: a combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers. Mol Psychiatry 22:562–569
Landim RC, Edden RA, Foerster B, Li LM, Covolan RJ, Castellano G, Legendre P (2001) The glycinergic inhibitory synapse. Cell Mol Life Sci:793
Mangia S, Tkac I, Gruetter R, Van de Moortele PF, Maraviglia B, Ugurbil K, McQueen G, Lally J, Collier T, Zelaya F, Lythgoe DJ, Barker GJ, Stone JM, McGuire P, MacCabe JH, Egerton A (2018) Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia. Psychopharmacology 235:3045–3054
Mekle R, Mnynarik V, Gambarota G, Hertg M, Krueger G, Gruetter R (2009) MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med 61:1279–1285
Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK (2016) Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry 73:665–674
Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, Mao X, Rodriguez CI, Oquendo MA, Suckow RF, Cooper TB, Keilp JG, Shungu DC, Mann JJ (2016) A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry 21:320–327
Moffett RJ, Ross B, Amm P, Madhavarao CN, Namboodiri AM (2007) N-Acetylaspafartate in the CNS: from neurodiagnostics to neurobiology. ProgNeurobiol 81:89–131
Moghaddam B, Javitt D (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37:4–15
Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17
Moriguchi S, Takamiyama A, Noda Y, Horita N, Wada M, Tsugawa S, Plitman E, Sano Y, Tarumi R, ElSahl MY, Katayama N, Oguy M, Miyazaki T, Kishimoto T, Graft-Guerrero A, Meyer JH, Blumberger DM, Daskalakis ZJ, Mimura M, Nakajima S (2018) Glutamatergic neuremtabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Mol Psychiatry
Mosier P, Hingsel L, Strasser B, Povazan M, Hangel G, Andrenesi OC, van der Kouwe A, Gruber S, Tratting S, Bogner W (2019) Whole-slice mapping of GABA and GABA(*) at 7T via adiabatic MEGA-editing, real-time instability correction, and concentric circle read-out. Neuroimage 184:475–489
Mullins PG (2018) Towards a theory of functional magnetic resonance spectroscopy (fMRS): a meta-analysis and discussion of using MRS to measure changes in neurotransmitters in real time. Scand J Psychol 59:91–103
Mullins PG, Chen H, Xu J, Caprihan A, Gasparovic C (2008) Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn Reson Med 60:964–969
Myers JF, Evans CJ, Kalk NJ, Edden RA, Lingford-Hughes AR (2014) Measurement of GABA using J-difference edited 1H-MRS following modulation of synaptic GABA concentration with tiagabine. Synapse 68:355–362
Napolitano A, Shah K, Porkess V, Fone KC, Auer DP, van der Kouwe A, Gruber S, Tratting S, Bogner W (2019) Whole-slice mapping of GABA and GABA(*) at 7T via adiabatic MEGA-editing, real-time instability correction, and concentric circle read-out. Neuroimage 184:475–489
O’Gorman Tuura R, Warnock G, Ametamey S, Teyyer V, Noeske R, Buck A, Sommerauer M (2019) Imaging glutamate redistribution after acute N-acetylcysteine administration: a simultaneous PET/MR study. Neuroimage 184:826–833
Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S, Wroblewska B, Bzdgea T, Vicini S, Barton FB, Neale JH (2004) NAAG peptidase inhibition reduces locomotor
activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 89:876–885

Patel AB, de Graaf RA, Martin DL, Battaglioni G, Behar KL (2006) Evidence that GAD65 mediates increased GABA synthesis during intense neuronal activity in vivo. J Neurochem 97:385–396

Pfeuffer J, Tkac I, Provencher SW, Gruetter R (1999) Toward an in vivo approach for the quantification of metabolite concentrations from short-echo-time 1H NMR spectra of the rat brain. J Magn Reson 141:104–120

Pillinger T, Rogdaki M, McCUTCheon RA, Hathway P, Egerton A, Howes OD (2019) Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. Psychopharmacology 236:1985–1997

Pliitman E, de la Fuente-Sandoval C, Reyes-Madrigal F, Chavez S, Provencher SW (1993) Estimation of metabolite concentrations from proton magnetic resonance spectroscopy studies with implications for gllal dysfunction. Schizophr Bull 42:415–424

Prescot AP, de Frederick B, Wang L, Jensen JE, Kaufman MJ, Renshaw PF (2006) In vivo detection of brain glycine with echo-time-averaged 1H magnetic resonance spectroscopy at 4.0 T. Magn Reson Med 55:681–686

Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672–679

Puts NA, Edden RA (2012) In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog Nucl Magn Reson Spectrosc 60:29–41

Rizzo F, Abari A, Nespoli E, Fegert JM, Hengerer B, Rasche V, Boeckers TM (2017) Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal (1)H-NMR spectroscopy study at 11.7T. Transl Psychiatry 7:e1189

Rodriguez CI, Kegeles LS, Levinson A, Ogden RT, Mao X, Milak MS, Vermes D, Xie S, Hunter L, Flood P, Moore H, Shungu DC, Simpson HB (2015) In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: a proton magnetic resonance spectroscopy study with implications for glial dysfunction. Schizophr Bull 42:415–424

Prescot AP, de Frederick B, Wang L, Brown J, Kaufman MJ, Renshaw PF (2006) In vivo detection of brain glycine with echo-time-averaged 1H magnetic resonance spectroscopy at 4.0 T. Magn Reson Med 55:681–686

Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672–679

Puts NA, Edden RA (2012) In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog Nucl Magn Reson Spectrosc 60:29–41

Rizzo F, Abari A, Nespoli E, Fegert JM, Hengerer B, Rasche V, Boeckers TM (2017) Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal (1)H-NMR spectroscopy study at 11.7T. Transl Psychiatry 7:e1189

Rodriguez CI, Kegeles LS, Levinson A, Ogden RT, Mao X, Milak MS, Vermes D, Xie S, Hunter L, Flood P, Moore H, Shungu DC, Simpson HB (2015) In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: a proton magnetic resonance spectroscopy study with implications for glial dysfunction. Schizophr Bull 42:415–424

Rothman DL, Sibson NR, Hyder F, Shen J, Behar KL, Shulman RG (1997) In vivo 13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling. Proc Natl Acad Sci U S A 94:2699–2704

Sibson NR, Mason GF, Shen J, Cline GW, Herskovits AZ, Wall JE, Behar KL, Rothman DL, Shulman RG (2001) In vivo (13)C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during. J Neurochem 76:975–989

Snyder J, Wilman A (2010) Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7T. J Magn Reson 203

Steel A, Chiew M, Jezzard P, Voets NL, Plaha P, Thomas MA, Stagg CJ, Emir UE (2018) Metabolite-cycled density-weighted concentric rings k-space trajectory (DW-CRT) enables high-resolution 1H magnetic resonance spectroscopic imaging at 3-Tesla. Sci Rep 8:7792

Stone JM, Dietrich C, Edden R, Mehta MA, De SS, Reed LJ, Krystal JH, Nutt D, Barker GJ (2012) Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychosis. Biol Psychiatry 162:1379–1386

Strzelecki D, Podgorski M, Kaluzynska O, Gawklik-Kotelniczka O, Stefanczyk L, Kotlicka-Antczak M, Gmitrowicz A, Grzelak P (2015a) Supplementation of antipsychotic treatment with sarcosine - GLyT1 inhibitor - causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. Neurosci Lett 606:7–12

Strzelecki D, Podgorski M, Kaluzynska O, Gawklik-Kotelniczka O, Stefanczyk L, Kotlicka-Antczak M, Gmitrowicz A, Grzelak P (2015b) Supplementation of antipsychotic treatment with the amino acid sarcosine influences proton magnetic resonance spectroscopy parameters in left frontal white matter in patients with schizophrenia. Nutrients 7:8767–8782

Strzelecki D, Podgorski M, Kaluzynska O, Stefanczyk L, Kotlicka-Antczak M, Gmitrowicz A, Grzelak P (2015c) Adding sarcosine to antipsychotic treatment in patients with stable schizophrenia changes the concentrations of neuronal and glial metabolites in the left dorsolateral prefrontal cortex. Int J Mol Sci 16:24475–24489
Szulc A, Konarzewska B, Galinska-Skok B, Lazareczyk J, Waszkiewicz N, Tarasow E, Milewski R, Walecki J (2013) Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia. Neurosci Lett 547:37–41
Taylor MJ (2014) Could glutamate spectroscopy differentiate bipolar depression from unipolar? J Affect Disord 167:80–84
Taylor MJ, Tiananga ER, Mhuircheartaigh RN, Cowen PJ (2012) Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. J Psychopharmacol 26:733–737
Terpstra M, Cheong I, Lyu T, Deelchand DK, Emir UE, Bednarik P, Eberly LE, Oz G (2016) Test-retest reproducibility of neurochemical profiles with short-echo, single-voxel MR spectroscopy at 3T and 7T. Magn Reson Med 76:1083–1091
Tiwari V, An Z, Ganji SK, Baxter J, Patel TR, Pan E, Mickey BE, Maher EA, Pinho MC, Choi C (2017) Measurement of glycine in healthy and tumorous brain by triple-refocusing MRS at 3T in vivo. NMR Biomed 30
Tkac I, Andersen P, Adriany G, Merkle H, Ugurbil K, Guetter R (2001) In vivo 1H NMR spectroscopy of the human brain at 7T. Magn Reson Med 46:451–456
Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M, Doty L, Adams LJ, Vengeliene V, Spanagel R, Zhang Y, Shen J, George DT, Hommer D, Heilig M (2010) Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry 67:1069–1077
Urenjak J, Williams SR, Gadian DG, Noble M (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13:981–989
Valentine GW, Mason GF, Gomez R, Basula M, Watzl J, Pittman B, Krystal JH, Sanacora G (2011) The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 191:122–127
Venkatraman TN, Krishnan RR, Steffens DC, Song AW, Taylor WD (2009) Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression. Psychiatry Res 172:49–54
Vernon AC, So PW, Lythgoe DJ, Chege W, Cooper JD, Williams SC, Kapur S (2015) Longitudinal in vivo maturational changes of metabolites in the prefrontal cortex of rats exposed to polyinosinic-polycytidylic acid in utero. Eur Neuropsychopharmacol 25:2210–2220
Waschkies CF, Bruns A, Muller S, Kapps M, Borroni E, von Kienlin M, Rudin M, Kunnecke B (2014) Neuropsychological and neurobiological relevance of in vivo (1)H-MRS of GABA and glutamate for preclinical drug discovery in mental disorders. Neuropsychopharmacology 39:2331–2339
Westbrook GL, Mayer ML, Namboodiri MA, Neale JH (1986) High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture. J Neurosci 6:3385–3392
Wijtenburg SA, Knight-Scott J (2011) Very short echo time improves the precision of glutamate detection at 3T in 1H magnetic resonance spectroscopy. J Magn Reson Imaging 34:645–652
Wong DF, Tauscher J, Gruetter R (2009) The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 34:187–203
Xi ZX, Kiyatkin M, Li X, Peng XQ, Wiggins A, Spiller K, Li J, Gardner EL (2010a) N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats. Neuropharmacology 58:304–313
Xi ZX, Li X, Peng XQ, Li J, Chun L, Gardner EL, Thomas AG, Shusher BS, Ashby CR Jr (2010b) Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism. J Neurochem 112:564–576
Xu S, Yang J, Li CQ, Zhu W, Shen J (2005) Metabolic alterations in focally activated primary somatosensory cortex of alphachloralose-anesthetized rats measured by 1H MRS at 11.7 T. Neuroimage 28
Yoo CH, Song KH, Lim SI, Lee DW, Woo DC, Cho BY (2017) Effects of repeated dizocilpine treatment on glutamatergic activity in the prefrontal cortex in an animal model of schizophrenia: An in vivo proton magnetic resonance spectroscopy study at 9.4T. Neurosci Lett 637:57–63
Zhang Y, Shen J (2016) Simultaneous quantification of glutamate and glutamine by J-modulated spectroscopy at 3 Tesla. Magn Reson Med 76:725–732

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.